The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016;66:7–30.
   PubMed Web of Science ®Google Scholar
• Havrilesky LJ, Whitehead CM, Rubatt JM, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110:374–382.
   PubMed Web of Science ®Google Scholar
• Van Gorp T, Cadron I, Despierre E, et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. Br J Cancer. 2011;104:863–870.
   PubMed Web of Science ®Google Scholar
• Anastasi E, Marchei GG, Viggiani V, et al. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010;31:113–119.
   PubMed Web of Science ®Google Scholar
• Ferraro S, Braga F, Lanzoni M, et al. Serum human epididymis protein 4 vs. carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013;66:273–281.
   PubMed Web of Science ®Google Scholar
• Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2 Group: QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155:529–536.
   PubMed Web of Science ®Google Scholar
• Deeks JJ. Systematic reviews of evaluation of diagnostic and screening tests. In: Egger M, Smith GD, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ Publishing; 2001. p. 248–282.
   Google Scholar
• Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: dataanalytic approaches and some considerations. Sta Med. 1993;12:1293–1316.
   PubMed Web of Science ®Google Scholar
• Dong L, Chang XH, Ye X, et al. The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy. Zhonghua Fu Chan Ke Za Zhi. 2008;43:931–936.
   PubMedGoogle Scholar
• Montagnana M, Lippi G, Ruzzenente O, et al. The utility of serum Human Epididymis Protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal. 2009;23:331–335.
   PubMed Web of Science ®Google Scholar
• Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5):1365–1372. DOI:10.1158/1055-9965.EPI-08-1034
   PubMed Web of Science ®Google Scholar
• Abdel-Azeez HA, Labib HA, Sharaf SM, et al. HE4 and mesothelin: novel biomarkers of ovarian carcinoma inpatients with pelvic masses. Asian Pac J Cancer Prev. 2010;11:111–116.
   PubMed Web of Science ®Google Scholar
• Andersen MR, Goff BA, Lowe KA, et al. Use of a symptom index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol. 2010;116:378–383.
   PubMed Web of Science ®Google Scholar
• Escudero JM, Auge JM, Filella X, et al. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clin Chem. 2011;57:1534–1544.
   PubMed Web of Science ®Google Scholar
• Korse CM, Bonfrer JMG, Van Beurden M, et al. The diagnostic and prognostic value of HE4 and CA125 in ovarian cancer patients. In: Tumor biology. 2010. p. s111–s111.
   Google Scholar
• Liu YN, Ye X, Cheng HY, et al. Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors. Zhonghua Fu Chan Ke Za Zhi. 2010;45:363–366.
   PubMedGoogle Scholar
• Nolen B, Velikokhatnaya L, Marrangoni A, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117(3):440–445.
   PubMed Web of Science ®Google Scholar
• Baba DU, Ugur M, Gungor T, et al. Clinical importance of Human Epidydimis Protein-4 (He4) in predicting malignancy potentials of adnexial masses. In: European Society of Gynecologic Oncology (ESGO 2011). Milan; 2011 Nov 15. p. 6–6.
   Google Scholar
• Bandiera E, Romani C, Specchia C, et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiol Biomarkers Prev. 2011;20:2496–2506.
   PubMed Web of Science ®Google Scholar
• Chang X, Ye X, Dong L, et al. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma. Int J Gynecol Cancer. 2011;21:852–858.
   PubMed Web of Science ®Google Scholar
• Cramer DW, Bast RC Jr, Berg CD, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal,and ovarian cancer screening trial specimens. Cancer Prev Res (Phila). 2011;4:365–374.
   PubMed Web of Science ®Google Scholar
• Franchi D, Sandri M, Boveri S, et al. Ultrasound imaging compared to a multivariate predictive algorithm combining HE4 and CA 125 (ROMA) in the pre-operative assessment of adnexal masses. Ultrasound Obstet Gynecol. 2011;38:1–55.
   PubMed Web of Science ®Google Scholar
• Granatova J, Boirecka K, Tuma J, et al. He4: A novel tumor marker in differential diagnostics of ovarian cancer. In: Clinical Chemistry and Laboratory Medicine. Vol. 49 SUPPL 1. 2011. p. S240.
   Google Scholar
• Kim YM, Whang DH, Park J, et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clin Chem Lab Med. 2011 Mar;49(3):527–534. Epub 2011 Feb 15. DOI:10.1515/CCLM.2011.085
   PubMed Web of Science ®Google Scholar
• Lenhard M, Stieber P, Hertlein L, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med. 2011;49:2081–2088.
   PubMed Web of Science ®Google Scholar
• Modares-Gilani M, Ghaemmaghami F, Mousavi A, et al. Simultaneous measurement of two serum markers (CA-125 and HE-4) while diagnosing malignant ovarian epithelial tumors. Pak J Med Sci. 2011;4:858–861.
   Google Scholar
• Molina R, Escudero JM, Auge JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biol. 2011;32:1087–1095.
   PubMed Web of Science ®Google Scholar
• Montagnana M, Danese E, Ruzzenente O, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011 Mar;49(3):521–525. Epub 2011 Feb 3. DOI:10.1515/CCLM.2011.075
   PubMed Web of Science ®Google Scholar
• Park Y, Lee JH, Hong DJ, et al. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases. Clin Biochem. 2011 Jul;44(10–11):884–888. Epub 2011 Apr 22. DOI:10.1016/j.clinbiochem.2011.04.011
   PubMed Web of Science ®Google Scholar
• Ruggeri G, Bandiera E, Zanotti L, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clin Chim Acta. 2011;412:1447Y1453.
   Web of Science ®Google Scholar
• Yip P, Chen TH, Seshaiah P, et al. Comprehensive serum profiling for the discovery of epithelial ovarian cancer biomarkers. PLoS One. 2011;6(12):e29533. Epub 2011 Dec 21. DOI:10.1371/journal.pone.0029533
   PubMed Web of Science ®Google Scholar
• Partheen K, Kristjansdottir B, Sundfeldt K, et al. Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. J Gynecol Oncol. 2011 Dec;22(4):244–252. Epub 2011 Dec 5. DOI:10.3802/jgo.2011.22.4.244
   PubMed Web of Science ®Google Scholar
• Anton C, Carvalho FM, Oliveira EI, et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics. 2012;67:437–441.
   PubMed Web of Science ®Google Scholar
• Freydanck MK, Laubender RP, Rack B, et al. Two-marker combinations for preoperative discrimination of benign and malignant ovarian masses. Anticancer Res. 2012;32:2003–2008.
   PubMed Web of Science ®Google Scholar
• He G, Holcroft CA, Beauchamp MC, et al. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours. J Obstet Gynaecol Can. 2012;34:567–574.
   PubMedGoogle Scholar
• Jacob F, Meier M, Caduff R, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol. 2011;121:487–491.
   PubMed Web of Science ®Google Scholar
• Kadija S, Stefanovic A, Jeremic K, et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer. 2012 Feb;22(2):238–244. DOI:10.1097/IGC.0b013e318234f852
   PubMed Web of Science ®Google Scholar
• Karlsen MA, Sandhu N, Høgdall C, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2012 Nov;127(2):379–383. Epub 2012 Jul 24. DOI:10.1016/j.ygyno.2012.07.106
   PubMed Web of Science ®Google Scholar
• Zheng H, Gao Y. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease. Int J Gynecol Cancer. 2012 Jul;22(6):1000–1005. DOI:10.1097/IGC.0b013e318249bee7
   PubMed Web of Science ®Google Scholar
• Li K, Yang Y, Li-Zhen H, et al. Significance of combined determination of serum HE4 CA125 level and T lymphocyte subgroups in peripheral blood in early diagnosis of ovarian cancer. Chin J Biologicals. 2012;25:99Y101.
   Google Scholar
• Novotny Z, Presl J, Kucera R, et al. HE4 and ROMA index in Czech postmenopausal women. Anticancer Res. 2012 Sep;32(9):4137–4140.
   PubMed Web of Science ®Google Scholar
• Park Y, Kim Y, Lee EY, et al. Reference ranges for HE4 and CA125 in a large Asian population by automated assays and diagnostic performances for ovarian cancer. Int J Cancer. 2012 Mar 1;130(5):1136–1144. Epub 2011 Jun 14. DOI:10.1002/ijc.26129
   PubMed Web of Science ®Google Scholar
• Azzam AZ, Hashad DI, Kamel NA. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? Arch Gynecol Obstet [Abstracts]. 2013;288:167–172.
   PubMed Web of Science ®Google Scholar
• Chan KK, Chen CA, Nam JH, et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecol Oncol. 2013;128:239–244.
   PubMed Web of Science ®Google Scholar
• Hamed EO, Ahmed H, Sedeek OB, et al. Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol [Abstract]. 2013;8:11.
   PubMed Web of Science ®Google Scholar
• Sandri MT, Bottari F, Franchi D, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecol Oncol. 2013 Feb;128(2):233–238. Epub 2012 Nov 28. DOI:10.1016/j.ygyno.2012.11.026
   PubMed Web of Science ®Google Scholar
• Fujiwara H, Suzuki M, Takeshima N, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumour Biol. 2015 Feb;36(2):1045–1053. Epub 2014 Oct 19. DOI:10.1007/s13277-014-2738-7
   PubMed Web of Science ®Google Scholar
• Cho HY, Park SH, Park YH, et al. Comparison of HE4, CA125, and risk of ovarian malignancy algorithm in the prediction of ovarian cancer in Korean women. J Korean Med Sci. 2015 Dec;30(12):1777–1783. Epub 2015 Nov 30. DOI:10.3346/jkms.2015.30.12.1777
   PubMed Web of Science ®Google Scholar
• Zhang P, Wang C, Cheng L, et al. Comparison of HE4, CA125, and ROMA diagnostic accuracy: a prospective and multicenter study for Chinese women with epithelial ovarian cancer. Medicine (Baltimore). 2015 Dec;94(52):e2402. DOI:10.1097/MD.0000000000002402
   PubMed Web of Science ®Google Scholar
• Romagnolo C, Leon AE, Fabricio AS, et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecol Oncol. 2016 May;141(2):303–311. Epub 2016 Jan 19. DOI:10.1016/j.ygyno.2016.01.016
   PubMed Web of Science ®Google Scholar
• Zhao T, Hu W. CA125 and HE4: measurement tools for ovarian cancer. Gynecol Obstet Invest. 2016 Apr 29;81:430–435. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Yanaranop M, Anakrat V, Siricharoenthai S, et al. Is the risk of ovarian malignancy algorithm better than other tests for predicting ovarian malignancy in women with pelvic masses? Gynecol Obstet Invest. 2017;82(1):47–53.
   Google Scholar
• Li L, Wan J, Cai G, et al. Value of serum human epididymis secretory protein 4 as a marker for differential diagnosis of malignant and benign gynecological diseases of patients in southern China. Clin Chim Acta. 2016 Aug 1;459:170–176. Epub 2016 Jun 11. DOI:10.1016/j.cca.2016.06.010
   PubMed Web of Science ®Google Scholar
• Wei SU, Li H, Zhang B. The diagnostic value of serum HE4 and CA-125 and ROMA index in ovarian cancer. Biomed Rep. 2016 Jul;5(1):41–44. Epub 2016 May 19.
   PubMed Web of Science ®Google Scholar
• Terlikowska KM, Dobrzycka B, Witkowska AM, et al. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. J Ovarian Res. 2016 Jul 19;9(1):43. DOI:10.1186/s13048-016-0254-7
   PubMed Web of Science ®Google Scholar
• Paek J, Lee SH, Yim GW, et al. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2011 Oct;158(2):338–342. Epub 2011 Jun 17. DOI:10.1016/j.ejogrb.2011.05.021
   PubMed Web of Science ®Google Scholar
• Hynninen J, Auranen A, Dean K, et al. HE4 profile during primary chemotherapy of epithelial ovarian cancer. Int J Gynecol Cancer. 2011 Dec;21(9):1573–1578. DOI:10.1097/IGC.0b013e3182225509
   PubMed Web of Science ®Google Scholar
• Kong SY, Han MH, Yoo HJ, et al. Serum HE4 level is an independent prognostic factor in epithelial ovarian cancer. Ann Surg Oncol. 2012 May;19(5):1707–1712. Epub 2011 Jul 21. DOI:10.1245/s10434-011-1943-5
   PubMed Web of Science ®Google Scholar
• Kalapotharakos G, Asciutto C, Henic E, et al. High preoperative blood levels of HE4 predicts poor prognosis in patients with ovarian cancer. J Ovarian Res. 2012 Aug 21;5(1):20. DOI:10.1186/1757-2215-5-20
   PubMed Web of Science ®Google Scholar
• Trudel D, Têtu B, Grégoire J, et al. Human epididymis protein 4 (HE4) and ovarian cancer prognosis. Gynecol Oncol. 2012 Dec;127(3):511–515. Epub 2012 Sep 9. DOI:10.1016/j.ygyno.2012.09.003
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrøm M, Brandslund I, et al. The prognostic and predictive value of combined HE4 and CA-125 in ovarian cancer patients. Int J Gynecol Cancer. 2012 Nov;22(9):1474–1482. DOI:10.1097/IGC.0b013e3182681cfd
   PubMed Web of Science ®Google Scholar
• Braicu EI, Fotopoulou C, Van Gorp T, et al. Preoperative HE4 expression in plasma predicts surgical outcome in primary ovarian cancer patients: results from the OVCAD study. Gynecol Oncol. 2013 Feb;128(2):245–251. Epub 2012 Nov 21.
   PubMed Web of Science ®Google Scholar
• Angioli R, Plotti F, Capriglione S, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol. 2013 Mar;128(3):579–583. Epub 2012 Dec 7. DOI:10.1016/j.ygyno.2012.11.040
   PubMed Web of Science ®Google Scholar
• Yang Z, Luo Z, Zhao B, et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncol Lett. 2013 Jul;6(1):28–34. Epub 2013 May 8.
   PubMed Web of Science ®Google Scholar
• Braicu EI, Chekerov R, Richter R, et al. HE4 expression in plasma correlates with surgical outcome and overall survival in patients with first ovarian cancer relapse. Ann Surg Oncol. 2014 Mar;21(3):955–962. Epub 2013 Nov 12. DOI:10.1245/s10434-013-3347-1
   PubMed Web of Science ®Google Scholar
• Chen WT, Gao X, Han XD, et al. HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pac J Cancer Prev. 2014;15(1):101–105.
   PubMedGoogle Scholar
• Angioli R, Capriglione S, Aloisi A, et al. Can HE4 predict platinum response during first-line chemotherapy in ovarian cancer? Tumour Biol. 2014 Jul;35(7):7009–7015. Epub 2014 Apr 21. DOI:10.1007/s13277-014-1836-x
   PubMed Web of Science ®Google Scholar
• Kaijser J, Van Belle V, Van Gorp T, et al. Prognostic value of serum HE4 levels and risk of ovarian malignancy algorithm scores at the time of ovarian cancer diagnosis. Int J Gynecol Cancer. 2014 Sep;24(7):1173–1180. DOI:10.1097/IGC.0000000000000181
   PubMed Web of Science ®Google Scholar
• Chudecka-Głaz AM, Cymbaluk-Płoska AA, Menkiszak JL, et al. Serum HE4, CA125, YKL-40, bcl-2, cathepsin-L and prediction optimal debulking surgery, response to chemotherapy in ovarian cancer. J Ovarian Res. 2014 Jun 10;7:62. eCollection 2014. DOI:10.1186/1757-2215-7-62
   PubMed Web of Science ®Google Scholar
• Vallius T, Hynninen J, Auranen A, et al. Serum HE4 and CA125 as predictors of response and outcome during neoadjuvant chemotherapy of advanced high-grade serous ovarian cancer. Tumour Biol. 2014 Dec;35(12):12389–12395. Epub 2014 Sep 5.
   PubMed Web of Science ®Google Scholar
• Angioli R, Capriglione S, Aloisi A, et al. A predictive score for secondary cytoreductive surgery in recurrent ovarian cancer (SeC-Score): a single-centre, controlled study for preoperative patient selection. Ann Surg Oncol. 2015 Dec;22(13):4217–4223. Epub 2015 Mar 26. DOI:10.1245/s10434-015-4534-z
   PubMed Web of Science ®Google Scholar
• Tang Z, Chang X, Ye X, et al. Usefulness of human epididymis protein 4 in predicting cytoreductive surgical outcomes for advanced ovarian tubal and peritoneal carcinoma. Chin J Cancer Res. 2015 Jun;27(3):309–317. DOI:10.3978/j.issn.1000-9604.2015.06.01
   PubMed Web of Science ®Google Scholar
• Nassir M, Guan J, Luketina H, et al. The role of HE4 for prediction of recurrence in epithelial ovarian cancer patients-results from the OVCAD study. Tumour Biol. 2016 Mar;37(3):3009–3016. Epub 2015 Sep 29. DOI:10.1007/s13277-015-4031-9
   PubMed Web of Science ®Google Scholar
• Steffensen KD, Waldstrøm M, Brandslund I, et al. Identification of high-risk patients by human epididymis protein 4 levels during follow-up of ovarian cancer. Oncol Lett. 2016 Jun;11(6):3967–3974. Epub 2016 May 6.
   PubMed Web of Science ®Google Scholar
• Schummer M, Drescher C, Forrest R, et al. Evaluation of ovarian cancer remission markers HE4, MMP7 and mesothelin by comparison to the established marker CA125. Gynecol Oncol. 2012;125:65–69.
   PubMed Web of Science ®Google Scholar
• Granato T, Midulla C, Longo F, et al. Role of HE4, CA72.4, and CA125 in monitoring ovarian cancer. Tumour Biol. 2012;33:1335–1339.
   PubMed Web of Science ®Google Scholar
• Plotti F, Capriglione S, Terranova C, et al. Does HE4 have a role as biomarker in the recurrence of ovarian cancer? Tumour Biol. 2012;33:2117–2123.
   PubMed Web of Science ®Google Scholar
• Manganaro L, Michienzi S, Vinci V, et al. Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer. Oncol Rep. 2013;30:2481–2487.
   PubMed Web of Science ®Google Scholar
• Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361:170–177.
   PubMed Web of Science ®Google Scholar
• American College of O, Gynecologists Committee on Gynecologic P. Committee Opinion No. 477: the role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol. 2011;117:742–746.
   PubMedGoogle Scholar
• Smith RA, Manassaram-Baptiste D, Brooks D, et al. Cancer screening in the United States, 2015: a review of current American cancer society guidelines and current issues in cancer screening. CA Cancer J Clin. 2015;65:30–54.
   PubMed Web of Science ®Google Scholar
• Buys SS, et al. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. Jama. 2011;305:2295–2303.
   PubMed Web of Science ®Google Scholar
• Moyer VA, Force USPST. Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med. 2012;157:900–904.
   PubMed Web of Science ®Google Scholar
• Schorge JO, Modesitt SC, Coleman RL, et al. SGO white paper on ovarian cancer: etiology, screening and surveillance. Gynecol Oncol. 2010;119:7–17.
   PubMed Web of Science ®Google Scholar
• Brown DL, Andreotti RF, Lee SI, et al. ACR appropriateness criteria(c) ovarian cancer screening. Ultrasound. 2010;26:219–223.
   Web of Science ®Google Scholar
• Sharma A, Apostolidou S, Burnell M, et al. Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound Obstet Gynecol. 2012;40:338–344.
   PubMed Web of Science ®Google Scholar
• Jacobs IJ, Menon U, Ryan A, et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2016;387:945–956.
   PubMed Web of Science ®Google Scholar
• Menon U, Gentry-Maharaj A, Hallett R, et al. Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009;10:327–340.
   PubMed Web of Science ®Google Scholar
• Hellström I, Rayeraft J, Hayden-Ledbetter M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695–3700.
   PubMed Web of Science ®Google Scholar
• Buamah P. Benign conditions associated with raised serum CA-125 concentration. J Surg Oncol. 2000;75:264–265.
   PubMed Web of Science ®Google Scholar
• Lin JY, Qin JB, Li XY, et al. Diagnostic value of human epididymis protein 4 compared with mesothelin for ovarian cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13:5427–5432.
   PubMedGoogle Scholar
• Wu L, Dai ZY, Qian YH, et al. Diagnostic value of serum human epididymis protein 4 (HE4) in ovarian carcinoma: a systematic review and meta-analysis. Int J Gynecol Cancer. 2012;22:1106–1112.
   PubMed Web of Science ®Google Scholar
• Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2013;167(1):81–85.
   PubMed Web of Science ®Google Scholar
• Moore RG, Bast RC Jr. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. J Clin Oncol. 2007;25:4159–4161.
   PubMed Web of Science ®Google Scholar
• Rustin G, Van Der Burg M, Griffin C, et al., MRC OV05; EORTC 55955 investigators. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomized trial. Lancet. 2010;376:1155–1163.
   PubMed Web of Science ®Google Scholar